A Phase I Open Label study of GSK3359609 administered alone and in combination with anticancer agents in subjects with selected advanced solid tumors
Study of Experimental Drug GSK3359609 in Patients with Advanced Solid Tumors
Sponsor: GlaxoSmithKline
Enrolling: Male and Female Patients
IRB Number: AAAR8356
U.S. Govt. ID: NCT02723955
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: GSK3359609 is a drug that is a type of antibody. It is a kind of immunotherapy that targets the ICOS (anti-Inducible T cell Co-Stimulator) protein present on specific immune cells. ICOS is a cell receptor that enhances the immune response to foreign bodies, and which is expected to help your immune system find and fight cancer cells. It will also be called the ICOS study drug. The ICOS study drug has only been given to people who participated in this study. The ICOS study drug is not yet approved for doctors to treat patients with cancer. The study is being done to find out what effects, good or bad, it has on people with certain types of cancer. Cancer types include: bladder cancer, colon and rectal cancer, esophageal cancer, gynecologic cancers (cervical cancer), head and neck/oral cancers, lung cancer, melanoma, and prostate cancer.
This study is closed
Brian Henick, MD
Do You Qualify?
Are you 18 years or older? Yes No
Is your disease locally advanced/metastatic or has it recurred/not responded to treatment? Yes No
Has your disease recurred following standard therapy or are there no current standard therapies available for you? Yes No
Are you willing to undergo a biopsy before you start treatment and while you are on treatment? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator